Braidwell LP decreased its position in shares of CG Oncology, Inc. (NASDAQ:CGON - Free Report) by 4.2% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 3,170,875 shares of the company's stock after selling 138,632 shares during the quarter. CG Oncology accounts for 3.4% of Braidwell LP's portfolio, making the stock its 5th largest position. Braidwell LP owned about 4.73% of CG Oncology worth $119,637,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds also recently made changes to their positions in CGON. Amalgamated Bank lifted its stake in CG Oncology by 107.6% during the 3rd quarter. Amalgamated Bank now owns 1,621 shares of the company's stock valued at $61,000 after acquiring an additional 840 shares during the period. California State Teachers Retirement System purchased a new position in shares of CG Oncology during the first quarter valued at approximately $103,000. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in CG Oncology during the third quarter valued at approximately $241,000. Profund Advisors LLC purchased a new stake in CG Oncology in the second quarter worth approximately $300,000. Finally, SG Americas Securities LLC bought a new stake in CG Oncology in the 3rd quarter worth approximately $664,000. Institutional investors own 26.56% of the company's stock.
CG Oncology Stock Performance
Shares of CGON traded up $0.65 during mid-day trading on Friday, reaching $34.75. The stock had a trading volume of 199,837 shares, compared to its average volume of 641,138. The business has a fifty day moving average of $35.99 and a 200 day moving average of $34.68. CG Oncology, Inc. has a 12 month low of $25.77 and a 12 month high of $50.23.
CG Oncology (NASDAQ:CGON - Get Free Report) last issued its earnings results on Tuesday, November 12th. The company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.36) by $0.06. CG Oncology had a negative net margin of 10,642.98% and a negative return on equity of 18.97%. The company had revenue of $0.04 million during the quarter, compared to the consensus estimate of $0.30 million. Equities analysts forecast that CG Oncology, Inc. will post -1.31 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
CGON has been the topic of several research analyst reports. Roth Capital raised CG Oncology to a "strong-buy" rating in a report on Tuesday, August 27th. Royal Bank of Canada started coverage on CG Oncology in a report on Monday, September 23rd. They issued an "outperform" rating and a $66.00 target price on the stock. Roth Mkm initiated coverage on CG Oncology in a research note on Tuesday, August 27th. They set a "buy" rating and a $65.00 price target for the company. UBS Group started coverage on shares of CG Oncology in a research note on Thursday, October 24th. They issued a "buy" rating and a $60.00 price objective on the stock. Finally, Bank of America restated a "buy" rating and set a $65.00 target price on shares of CG Oncology in a research report on Tuesday, October 8th. Eight research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, CG Oncology currently has an average rating of "Buy" and an average price target of $63.88.
Check Out Our Latest Stock Analysis on CGON
About CG Oncology
(
Free Report)
CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.
Featured Articles
Before you consider CG Oncology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CG Oncology wasn't on the list.
While CG Oncology currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
